BSE: AHCL · Pharmaceuticals
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Anlon Healthcare Limited is a chemical manufacturing company specialising in the production of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company also provides custom manufacturing services for complex and novel chemical compounds.
The company generates revenue through the sale of high-purity chemical intermediates and APIs used in finished dosage formulations, nutraceuticals, and veterinary products. It further monetises its technical capabilities by offering custom manufacturing services for specialised chemical compounds.
Growth is driven by the recent expansion into custom manufacturing services for complex chemical compounds. The company continues to leverage its expertise in high-purity chemicals to serve diverse sectors including personal care and pharmaceuticals.
Unlock AI insights, financials, peers and live data on Anlon Healthcare and 5,000+ companies — free.
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Anlon HealthcareAHCL | ₹833 Cr | 2.81 | 18.34 | — | 27.4% | 13.9% | 21.3% | -82.8% |
Shree Ganesh Remedies LimitedSGRL | ₹909 Cr | 51.23 | 24.35 | — | 34.8% | 11.9% | 15.9% | +19.9% |
WanburyWANBURY | ₹860 Cr | 14.18 | 10.79 | 3.6% | 15.2% | 54.9% | 29.2% | -11.3% |
Anuh PharmaANUHPHR | ₹813 Cr | 22.65 | 11.21 | 9.7% | 9.2% | 13.0% | 17.7% | -5.1% |
Amanta HealthcarAMANTA | ₹753 Cr | 46.64 | 14.50 | — | 21.5% | 6.7% | 9.9% | — |
Bafna Pharmaceuticals LimitedBAFNAPH | ₹700 Cr | 89.92 | 41.24 | -3.1% | 12.5% | 8.6% | 10.3% | +195.9% |
As of Q1 FY27
Anlon Healthcare
BSE: AHCL · Pharmaceuticals
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Anlon Healthcare Limited is a chemical manufacturing company specialising in the production of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company also provides custom manufacturing services for complex and novel chemical compounds.
The company generates revenue through the sale of high-purity chemical intermediates and APIs used in finished dosage formulations, nutraceuticals, and veterinary products. It further monetises its technical capabilities by offering custom manufacturing services for specialised chemical compounds.
Growth is driven by the recent expansion into custom manufacturing services for complex chemical compounds. The company continues to leverage its expertise in high-purity chemicals to serve diverse sectors including personal care and pharmaceuticals.
Unlock AI insights, financials, peers and live data on Anlon Healthcare and 5,000+ companies — free.
As of Q1 FY27